U. Hasler-Strub

Type de document

Co-auteur

K. Zaman

R. Von Moos

A. Trojan

T. Ruhstaller

C. Rochlitz

R. Winterhalder

A. Wicki

M. Vetter

B. Thuerlimann

A. Schreiber

T. Rordorf

K. Ribi

D. Rauch

K.J. Na

A. Müller

A. Mueller

K. Matter-Walstra

Q. Li

M. Küng

A. Hochstrasser

S. Greuter

U. Gick

S. Gerber

M. Fehr

R. Condorelli

R. Cathomas

C.B. Caspar

M. Börner

M. Bigler

J. Bernhard

D. Bärtschi

D. Baertschi

S. Anchisi

S. Aebi

Date

Source

Serveur académique Lausannois (2)

Mot-clé

toxicité (2) thérapie (2) maladie (2) procès (2) cancer (2) taux (2) survie (2) Treatment (2) Chemotherapy (2) Control (2) Cancer (2) Rates (2) Ci (Chinese poetry) (2) Therapeutics (2) Survival (2) Patients (2) Chemotherapy (2) Cancer (2) Breast (2) Toxicology (2) Rates (2) Patients (2) maladie (2) étable (1) sécurité (1) enregistrement (1) qualité de vie (1) oncologie (1) neurotoxicité (1) infection (1)

Documents écrit par U. Hasler-Strub (2) | parle de U. Hasler-Strub (0)

Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].

U. Hasler-Strub et al.

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.

C. Rochlitz et al. (2016)